← Back to patent-cliff list
CAS 1050477-27-4
4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide(±)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Codes: FINE-009, (XI)638294-1-a, (XI)638294-2-a, (IX)638294-3-a,(IX)638294-3-b, (XIII)638294-5-b, (VIII)638294-15-a, (I)638294-19-a
Application context (from source-drug indications)
Systolic heart failureFinerenoneDiastolic heart failureFinerenoneHeart failureFinerenoneChronic renal impairmentFinerenoneDiabetic nephropathyFinerenoneType 2 diabetesFinerenone
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Finerenone | Tier C — Watch / trade | 2030 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
tert-butyl (E)-3-(4-cyano-2-methoxyphenyl)acrylate→4-formyl-3-methoxybenzonitrile→2-cyanoethyl 3-oxobutanoate→2-cyanoethyl (Z)-2-(4-cyano-2-methoxybenzylidene)-3-oxobutanoate→4-amino-5-methylpyridin-2(1H)-one→2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate→2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate→4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid→4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
2,2-Dimethyl-6-methyl-1,3-dioxin-4-one→1-Cyano-2-hydroxyethane→2-Cyanoethyl 3-oxobutanoate→2-Methoxy-4-cyanobenzaldehyde→2-Cyanoethyl (2Z)-2-[(4-cyano-2-methoxyphenyl)methylene]-3-oxobutanoate→4-Amino-5-methylpyridin-2(1H)-one→2-Cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate→(Diethoxymethoxy)ethane→1,1,1-Triethoxyethane→2-Cyanoethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate→4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid→(±)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,6-naphthyridine-3-carboxamide
4-Bromo-2-hydroxybenzoic acid→2-Methoxy-4-bromobenzoic acid methyl ester→4-Bromo-2-methoxybenzaldehyde→2-Methoxy-4-cyanobenzaldehyde→3-Oxobutanamide→(2E)-2-[(4-Cyano-2-methoxyphenyl)methylidene]-3-oxobutanamide→(2Z)-2-[(4-Cyano-2-methoxyphenyl)methylidene]-3-oxobutanamide→4-Amino-5-methylpyridin-2(1H)-one→4-(4-Cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxamide→1,1,1-Triethoxyethane→(±)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→2,4-Dihydroxy-5-methylpyridine→1-Phenylmethylamine→4-(Benzylamino)-5-methylpyridin-2(1H)-one
4-Amino-5-methylpyridin-2(1H)-one→1-Iodoethane→2-Ethoxy-5-methylpyridin-4-amine→N-(2-Ethoxy-5-methylpyridin-4-yl)-2,2-dimethylpropanamide→2-Methoxy-4-cyanobenzaldehyde→N-[3-[(4-Cyano-2-methoxyphenyl)(hydroxy)methyl]-2-ethoxy-5-methylpyridin-4-yl]-2,2-dimethylpropanamide→4-[(4-Amino-2-ethoxy-5-methylpyridin-3-yl)(hydroxy)methyl]-3-methoxybenzonitrile→3-Oxobutanamide→(±)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,6-naphthyridine-3-carboxamide→(aS)-10,16-Di(anthracen-9-yl)-13-hydroxy-12,14-dioxa-13lambda5-phosphapentacyclo[13.8.0.02,11.03,8.018,23]tricosa-1(15),2(11),3,5,7,9,16,18,20,22-decaene 13-oxide
4-Amino-5-methylpyridin-2(1H)-one→(±)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide→4-Bromo-2-methoxybenzaldehyde→1-Cyano-2-propanone→4-(4-Bromo-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carbonitrile→(Diethoxymethoxy)ethane→4-(4-Bromo-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carbonitrile→4-(4-Bromo-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 4-Bromo-2-methoxybenzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-formyl-3-methoxybenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-AMino-5-Methylpyridin-2-ol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-5-methylpyridin-4-amine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Cyanoethyl 3-oxobutanoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.